文献速递糖尿病肥胖与代谢综合征

真实世界临床实践中2型糖尿病对GLP-1受体激动剂反应的异质性:来自DPV登记研究的IMI-SOPHIA项目见解

Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register - an IMI-SOPHIA study.
PubMed 文献 · Diabetologia · 2025-05-22

基于DPV登记研究中4467例2型糖尿病成人,分析启动利拉鲁肽、司美格鲁肽或度拉糖肽后6个月内HbA1c和体重变化。仅14%的参与者同时达到HbA1c绝对降低≥5.5 mmol/mol(0.5%)和体重相对降低≥5%。结论认为常规临床实践中对GLP-1 RA治疗的反应存在显著异质性,但相当比例实现了体重或HbA1c其一的降低。

要点

  • 6个月随访时HbA1c中位绝对降低5.3 mmol/mol(IQR 13.9,-1.0),体重中位相对降低1.43%(4.26,0)。
  • 仅14%的参与者同时达到HbA1c绝对降低≥5.5 mmol/mol(0.5%)和体重相对降低≥5%。
  • 男性及基线HbA1c较高者更可能仅HbA1c达标(占36%,均p<0.001);年龄较大及糖尿病病程较长者更可能仅体重达标(占7%,均p<0.001)。

核心结论

  • 常规临床实践中2型糖尿病患者对GLP-1 RA治疗的反应存在显著异质性,但研究中相当比例实现了体重或HbA1c之一的降低。
  • 未来研究应探索为何部分个体仅实现体重降低或仅HbA1c降低而未能两者兼得。

研究设计与样本

  • 分析DPV登记研究中4467例2型糖尿病成人,聚焦启动利拉鲁肽、司美格鲁肽或度拉糖肽后6个月内HbA1c和体重的变化。
  • 根据反应将参与者分类为:仅HbA1c降低、仅体重降低、两者兼具或两者均无。
  • 本分析是IMI-SOPHIA项目的一部分。

主要发现

  • 6个月随访时HbA1c中位绝对降低5.3 mmol/mol(IQR 13.9,-1.0)(0.49% [1.27, -0.09]),体重中位相对降低1.43%(4.26,0)。
  • 仅14%的参与者同时达到HbA1c绝对降低≥5.5 mmol/mol(0.5%)和体重相对降低≥5%。
  • 男性及基线HbA1c较高者更可能仅HbA1c达标(占36%,均p<0.001)。
  • 年龄较大及糖尿病病程较长者更可能仅体重达标(占7%,均p<0.001)。
  • 基线体重较高及eGFR较低(均p<0.05)与更大体重降低相关;基线HbA1c较低及糖尿病病程较长与更小HbA1c降低相关(均p<0.001)。

关键数值与推荐

  • HbA1c绝对降低≥5.5 mmol/mol(0.5%)和体重相对降低≥5%被定义为有意义的降低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a cornerstone in type 2 diabetes management. In this study we evaluated heterogeneity in body weight and glycaemic responses to the initiation of liraglutide, semaglutide or dulaglutide in real-world clinical practice. METHODS: Data from 4467 adults with type 2 diabetes in the Diabetes Patient Follow-up (DPV) registry were analysed, focusing on changes in HbA1c and body weight over 6 months following initiation of a GLP-1 RA. We categorised participants based on their response: HbA1c reduction only, weight loss only, both or neither. This analysis was part of the IMI-Stratification of Obesity Phenotypes to Optimize Future Obesity Therapy (IMI-SOPHIA) project. RESULTS: At 6 months' follow-up the median absolute HbA1c reduction was 5.3 mmol/mol (IQR 13.9, -1.0) (0.49% [1.27, -0.09]) and relative body weight reduction was 1.43% (4.26, 0). Only 14% of participants achieved meaningful reductions in both HbA1c (absolute reduction ≥5.5 mmol/mol [0.5%]) and body weight (relative reduction ≥5%). Men and those with a higher baseline HbA1c were more likely to show an HbA1c only response (36% of participants; both p<0.001), while older individuals and those with a longer diabetes duration were more likely to experience a weight-only response (7% of participants; both p<0.001). Higher baseline body weight and lower eGFR (both p<0.05) correlated with greater weight reduction, whereas lower baseline HbA1c and longer diabetes duration were linked to smaller HbA1c reductions (both p<0.001). CONCLUSIONS/INTERPRETATION: There is significant heterogeneity in responses to GLP-1 RA therapy among individuals with type 2 diabetes in routine clinical practice. However, in our study a substantial proportion achieved a reduction in either body weight or HbA1c. Future studies should explore why some individuals achieve either weight loss or HbA1c reduction but not both.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Heni M, Frühwald L, Karges W, et al. Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register - an IMI-SOPHIA study. Diabetologia. 2025. PMID: 40404820. doi:10.1007/s00125-025-06448-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。